Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05110157 · ClinicalTrials.gov registry record · Phase 3
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
A Phase 3 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 442
- Enrollment target
NCT05110157 is a Phase 3 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 442 participants.
The verdict
NCT05110157, a Phase 3 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 442 participants
- Enrollment target
Study Summary
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Interventions
- DRUG Placebo
- DRUG Valbenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2025-02-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05110157
The ClinicalTrials.gov registry entry for NCT05110157 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 442 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05110157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05110157 about?
NCT05110157 is a clinical study titled "Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia". The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
What is the current status of trial NCT05110157?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 442 participants. The study started on 2021-11-29. Estimated completion is 2025-02-18.
What interventions are being tested in trial NCT05110157?
The interventions under investigation include: Placebo (DRUG), Valbenazine (DRUG).
Who is sponsoring clinical trial NCT05110157?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.